Citations

Clear

16280 citation(s) found for "Yu, David".

Abstract 245: Super‐Large‐Bore vs Large‐Bore Aspiration Catheters in Mechanical Thrombectomy: A Multicenter Propensity‐Matched Analysis
Chacon, Alexander , Inoa, Violiza , Cawley, M. F., Rai, Ansaar , Maier, Ilko , Dye, J. A., Ezzeldin, M., Matouk, Charles, Brinjikji, Waleed , Jabbour, Pascal , Almallouhi, E., Dağlıoğlu, Ergün , Spiotta, Alejandro M , Grossberg, Jonathan A , Chacon, A., Alawieh, Ali , Motiwala, Mustafa , Arthur, Adam Stephen , Cawley, M., Howard, Brian M , Siddiqui, F., Alaraj, Ali , Romano, Daniele Giuseppe , Fiorella, David , Dye, J., Wolfe, Stacey Q , Mascitelli, Justin R , Fragata, Isabel , Limaye, Kaustubh , Ogilvy, Christopher S. , Jabbour, Pascal , Almallouhi, Eyad , Park, M. S., Navía, Pedro , Grandhi, Ramesh , Altschul, David , Schirmer, Clemens M. , Paul, Alexandra R , Mokin, Maxim , Goyal, Nitin

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_245 Get It

Background Contact aspiration remains a frontline approach for mechanical thrombectomy (MT) in acute ischemic stroke (AIS). Early evidence correlates catheter size with procedural efficiency and clinical outcomes. Larger‐bore (LB) aspiration catheters may enhance clot ingestion, increase aspiration force, and facilitate faster and more complete recanalization. However, the transition from standard LB catheters (0.068‐0.072″) to super‐large‐bore (SLB, ≥0.080″) devices has raised questions regarding both safety and clinical benefit. Although the use of SLB catheters is increasing, comparative data on their performance versus LB catheters remain limited. This study aims to evaluate the safety and efficacy of SLB compared with LB catheters including data from a large multicenter international registry. Methods We retrospectively analyzed patients with AIS due to LVO treated at 46 international stroke centers between January 2013 and June 2025. Among eligible patients, propensity score matching (PSM) at a 5:1 ratio was used to balance baseline characteristics between those treated with standard LB catheters and those treated with SLB catheters. Safety endpoints included intraprocedural complications, symptomatic intracranial hemorrhage (sICH), distal embolization, and 90‐day mortality. Efficacy endpoints included functional independence at 90 days (modified Rankin Scale [mRS] 0‐2), successful recanalization (TICI ≥2b), first‐pass effect (TICI ≥2b on the first aspiration attempt), and procedural timing to TICI2b. Results A total of 3,100 patients were included (LB n=3,024; SLB n=67). After PSM (LB n=335; SLB n=67), safety outcomes were comparable between groups in terms of intraprocedural complications occurred (p=0.5), sICH (p>0.9), embolization to new territory (p=0.2), and 90‐day mortality (p>0.9). Efficacy outcomes were similarly consistent for functional independence (mRS 0‐2) (p>0.9), successful recanalization (p>0.9), first‐pass effect (p=0.5), and time to TICI ≥2b (27.6 vs. 24.5 minutes; p=0.9). These findings remained consistent in the subgroup with ICA and M1 occlusions, with no significant differences in safety (intraprocedural complications [p=0.4], sICH [p>0.9], embolization to new territory [p=0.6], or 90‐day mortality [p>0.9], nor in efficacy outcomes (functional independence at 90 days [p>0.9], successful recanalization [p=0.9], first‐pass effect [p=0.6], and time to TICI ≥2b [p=0.9]). Conclusion In this large multicenter analysis, the use of SLB aspiration catheters demonstrated comparable safety and efficacy to standard LB catheters for MT in AIS. Despite theoretical advantages in aspiration dynamics, SLB devices did not confer significant procedural or clinical benefit over LB catheters. These findings suggest that while SLB catheters are a feasible alternative, technical and clinical outcomes remain comparable to LB catheters. Further prospective studies are warranted to clarify potential clinical advantages. image
Abstract 217: Outcomes of Combined Mechanical Thrombectomy Versus Stent Retriever or Contact Aspiration in Acute Ischemic Stroke: An Updated Network Meta‐Analysis
Hamouda, A. M., Kendall, Nicholas , Elgohary, Mostafa, Arumaithurai, Kogulavadanan , Kadirvel, Ramanathan , Brinjikji, Waleed , Kallmes, David F. , Derhab, Mohamed , Hamouda, A. M., Pennington, Zach , Kumar, Rahul , Elgohary, M., Ghozy, Sherief

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_217 Get It

Introduction For large vessel occlusion (LVO) ischemic strokes, three major techniques of mechanical thrombectomy have demonstrated efficacy. In this study, we compared stent retrievers (SR),contact aspiration (Asp), and a combined approach to provide an updated comparison of key outcomes for each strategy. Methods We followed PRISMA guidelines to conduct a systematic review and meta‐analysis across PubMed, EMBASE, Scopus, and Web of Science databases up to September 2024. Studies were included if they included outcomes for patients with ischemic stroke who underwent mechanical thrombectomy using a stent retriever, contact aspiration, or a combination of both techniques. Results Twenty‐four studies comprising a total of 12,845 patients were included in the analysis. Compared to the Asp technique alone, the combined mechanical thrombectomy (MT) approach was associated with a higher risk of arterial dissection (RR: 2.00; 95% CI [1.15, 3.44]), longer procedure duration (MD: 13.35 minutes; 95% CI [5.87, 20.83]) and associated with a lower risk of arterial dissection (RR: 0.50; 95% CI [0.29, 0.87]). However, Asp was associated with a lower rate of first‐pass effect (FPE) compared to combined MT (RR: 0.67; 95% CI [0.46, 0.96]). Additionally, stent retriever (SR) use was linked to a higher procedure duration compared to Asp(MD: 13.39 minutes; 95% CI [5.55, 21.22]) and a lower FPE rate (RR: 0.75; 95% CI [0.59,0.96]). No significant differences were observed between groups in terms of successful recanalization, 90‐day functional outcomes, or mortality. Conclusion In our analysis, all three techniques demonstrated similar recanalization rates and functional outcomes. However, aspiration was associated with shorter procedure times and fewer arterialdis section complications, while the combination technique showed a higher first pass effect. Given the comparable overall efficacy, the choice of technique should be guided by the physician's preference, expertise, and confidence, tailored to the individual patient's profile.
Abstract 017: Determinants of Adequate Aneurysm Occlusion After WEB Device Deployment: Systematic Review and Meta‐Analysis
Lashin, Basant Ismail , Abbas, Alzhraa Salah , Liu, Michael , Hamam, Khaled M., Abo‐elnour, Dina Essam , Kadirvel, Ramanathan , Kallmes, David F. , Kallmes, D. F., Lashin, Basant , Ghozy, Sherief , Abbas, Alzhraa Salah , Butt, Abu Bakar , Salama, Esraa Y. , Patel, M., Cortese, Jonathan , Kallmes, D. F.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_017 Get It

Background The Woven EndoBridge (WEB) device is an effective treatment for wide‐neck aneurysms (WNA). This study aims to identify and compare anatomical and procedural factors that predicts the aneurysm occlusion, both adequate and inadequate after WEB device treatment. Methods A systematic review and meta‐analysis were conducted using PubMed, Embase, Scopus, and Web of Science, including studies up to October 25, 2024. Data on angiographic outcomes of WEB occlusion were extracted and analyzed using R version 4.4.2 Results Nine studies (790 patients) were included. Female patients were 1.64 times more likely to achieve adequate occlusion than males (OR: 1.64, 95% CI: [1.06, 2.52], p = 0.026). Regular‐shaped aneurysms had a 2.44‐fold higher likelihood of adequate occlusion compared to irregular ones (OR: 0.41, 95% CI: [0.23, 0.74]). Aneurysm neck size was significantly smaller in the adequate occlusion group (3.9 mm vs. 4.4 mm, MD: ‐0.48 mm, 95% CI: [‐0.78, ‐0.18], p = 0.002). Maximum aneurysm diameter was also smaller in the adequate occlusion group (5.7 mm vs. 6.8 mm, MD: ‐1.13 mm, 95% CI: [‐1.69, ‐0.57], p < 0.001). Aneurysm height was also significantly lower than the inadequate occlusion group (5.4 mm vs. 6.3 mm, MD: ‐0.92 mm, 95% CI: [‐1.55, ‐0.29], p = 0.004). Conclusion Smaller aneurysm dimensions, regular shape, and female gender were associated with higher adequate occlusion rates after WEB treatment. These findings may guide patient selection strategies for optimizing aneurysm occlusion. Further high‐quality studies are needed to confirm these associations. image image
Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Pope, Jill , Smith, Gregory L. , Goree, Johnathan , Mekhail, Nagy , Levy, Robert M. , Deer, Timothy R. , Vu, Chau , Shah, Jarna R , Costandi, Shrif , Rosen, Steven M., Bromberg, Todd A., Patel, Atish, Latif, Usman , Lad, Shivanand P. , Jameson, Jessica , Calodney, Aaron , Falowski, Steven , Smith, J. Carson , Guirguis, Maged , Boeding, Ronald B., Sprintz, Michael, Antony, Ajay, Patterson, Denis G., Laufer, Andras, Pilitsis, Julie G. , Miller, Nathan , Rosenfeld, David J. , Tate, Jordan L, Raslan, Ahmed M. , Kallewaard, Jan Willem , Leitner, Angela , Hanson, Erin, Soliday, Nicole, Petersen, Erika , Goree, Johnathan A , Mekhail, Nagy A , Costandi, Shrif J , Lam, Christopher M , Hayek, Salim , Hagedorn, Jonathan M , Kallewaard, Jan Willem , Duarte, Rui , Deer, Tim , Shah, Jarna , Rosen, Steven M, Sayed, Dawood , Lam, Christopher , Hayek, Salim M. , Hagedorn, Jonathan M. , Heros, Robert , Miller, Nathan, Tate, Jordan L, Hanson, Erin, Duarte, Rui

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107051

10.1136/rapm-2025-107051 | PMID 41330601 Get It

Background The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. Methods The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. Results EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. Conclusions EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
Optimizing procedures for ocular radiation injury studies in the tree shrew
Dalvin, Lauren A. , Anderson, Kjersten J. , Rinkoski, Tommy A. , Miley, David R. , Ong, Hien Thi My , Schechinger, Angela M., Fjeld, Cassandra A., Leblond, Catherine R. , Keown, Mackenzie K. , Palmer, Sierra D. , Carlson, Brett L. , Ott, Lauren L. , Romero, Michael F. , Boynton, Felicia D. Duke , Roddy, Gavin W. , Ong, Hien , Burgenske, Danielle M , Carlson, Brett L , Ott, Lauren L , Samuels, Brian C , Romero, Michael F , Sarkaria, Jann N , Boynton, Felicia Duke , Roddy, Gavin W , Dalvin, Lauren A , Burgenske, Danielle M. , Sarkaria, Jann N.

Mayo Clinic

Exploration of Targeted Anti-tumor Therapy | December 2, 2025 | Volume: 6 | Issue: No issue available | Pages: No page available

10.37349/etat.2025.1002352 | PMID 41357135 Get It

Radiation exposure to the eye during cancer treatment can lead to ocular radiation injury (ORI), a devastating condition that can have a profound and permanent impact on vision-related quality of life. Rodent models do not have adequate ocular anatomy to accurately simulate human ORI, and modeling in non-human primates is limited by logistical and ethical concerns. To improve future translational research investigating ways to treat or prevent ORI, we developed protocols for a tree shrew model of ORI. Northern tree shrews (Tupaia belangeri) were obtained by our laboratory. Custom housing and handling methods were developed, including custom body suits to maintain the tree shrew’s body temperature during procedures. Radiation delivery was optimized to accurately deliver radiation, and imaging was performed to observe fundus changes from ORI. Optimization of tree shrew handling, housing, anesthesia approaches, radiation delivery, and clinically-relevant ocular imaging permitted successful induction and assessment of ORI in tree shrews. With these protocols, tree shrews can be used as a highly relevant model organism with key anatomic features similar to humans to study ORI.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
PHYOX8: Nedosiran in Pediatric Patients with Primary Hyperoxaluria
Sas, David J. , Belostotsky, Vladimir , Iraola, María Gema Ariceta, Schalk, Gesa, Eid, Loai Akram, Yu, Jing , Arora, Jyoti , Bakkaloglu, Sevcan Azime

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025pb2wxtvm Get It

Kidney Survival in Patients with Primary Hyperoxaluria Type 1 Treated with Lumasiran Compared with Historical Controls
Sas, David J. , Vaughan, Lisa E. , Schulte, Phillip J. , Tencer, T. , Milliner, Dawn S. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025d7va7dp6 Get It

Reply to Abushanab et al. : Longitudinal Outcomes of Pi*MZ versus Pi*MM Subjects Stratified by Former and Current Smoking Status
Barjaktarević, Igor , Zhang, Zian , Buhr, Russell G. , Hixson, Roxana, Ortega, Victor E. , Buhr, Russell G , Ortega, Victor, Barjaktarevic, Igor , Tashkin, Donald P.

Mayo Clinic

Annals of the American Thoracic Society | December 1, 2025 | Volume: 22 | Issue: 12 | Pages: 1969-1970

10.1513/annalsats.202508-882le | PMID 41324341 Get It

Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study
Adamides, Alexios A. , Başkaya, Mustafa K. , Ieva, Antonio Di , Lawton, Michael T., Pinna, Giampietro, Podlesek, Dino , Radovanovic, Ivan, Rohde, Veit, Stroh-Holly, Nico , Sturiale, Carmelo Lucio, _, _, Fierstra, Jorn , Laidlaw, John D., Evans, Lachlan R. , Sayyahmelli, Sara, Sayyahmelli, Sima , Štekláčová, Anna , Morgan, Michael K. , Acerbi, Francesco , Oushy, Soliman , Rinaldo, Lorenzo , Thomé, Claudius , Geiger, Philipp , Musumeci, Angelo , Schackert, Gabriele , Bervini, David , Raabe, Andreas, Mansur, Ann , Olijnyk, Leonardo, Malinova, Vesna , Mielke, Dorothée , Gmeiner, Matthias , Gruber, Andreas , Kondajji, and Aditya M., Oushy, Soliman H , Bervini, David , Staartjes, Victor E. , Anania, Pasquale , Beneš, Vladimír , Dehdashti, Amir R. , Ferroli, Paolo , Jakola, Asgeir Store , Lanzino, Giuseppe , Lawton, Michael T. , Petr, Ondra , Petutschnigg, Thomas , Rohde, Veit , Sturiale, Carmelo Lucio , Wang, Anthony , Regli, Luca , Esposito, Giuseppe, _, _, Serra, Carlo , Sebök, Martina , Germans, Menno Robbert , Zona, Gianluigi , Fiaschi, Pietro , Yang, Kaiyun , Acerbi, Francesco , Vetrano, Ignazio G. , Klurfan, Paula , Catapano, Joshua S , Meneghelli, Pietro , Goldberg, Johannes , Gruber, Andreas, Auricchio, Annamaria , Olivi, Alessandro , Colby, Geoffrey P.

Mayo Clinic

Neurosurgical Focus | December 1, 2025 | Volume: 59 | Issue: 6 | Pages: E18

10.3171/2025.9.focus25723 | PMID 41343785 Get It

OBJECTIVE Objective values on procedural risk are essential to facilitate informed consent and optimize clinical decision-making in patients with unruptured intracranial aneurysms (UIAs). While robust heuristics, such as the PHASES (population, hypertension, age, size of aneurysm, earlier subarachnoid hemorrhage, and site of aneurysm) score, are established for predicting rupture risk, contemporary and granular benchmarks for procedural safety remain scarce. The multinational Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) study aims to comprehensively characterize contemporary adverse event rates following microsurgical treatment at high-volume expert centers, stratified by aneurysm location, morphology, and complexity factors to better inform individual risk/benefit analyses. METHODS A cohort study among 20 participating expert centers from 9 countries was established. Patients treated microsurgically for UIAs were included. The authors describe the epidemiology of treated patients and UIAs and a comprehensive adverse event profile using 3 outcomes measured at hospital discharge: 1) poor neurological outcome (modified Rankin Scale score ≥ 3), 2) new sensorimotor neurological deficits, and 3) all-cause adverse events (Clavien-Dindo grade ≥ 1). Subgroup reports were given for aneurysm location, morphology, and complexity factors (prior aneurysm treatment, calcifications, complex angioanatomy involving critical branch vessels or perforators, and thrombosis). The authors purposely chose discharge as the time point to capture early postoperative risks and complications in patients with asymptomatic UIAs, for whom preserving neurological function is paramount. RESULTS The cohort included 3705 patients (mean age 56 [SD 12] years, 28% male). Overall, at discharge 13.9% of patients (95% CI 12.8%–15.0%) had poor neurological functional outcomes, 14.4% (95% CI 13.3%–15.5%) had new sensorimotor deficits, and 24.1% (95% CI 22.8%–25.5%) experienced all-cause adverse events. Poor neurological outcomes ranged from 8.5% (M1 aneurysms) to 37.4% (posterior circulation aneurysms), neurological deficits from 9.3% (distal anterior cerebral artery [ACA] aneurysms) to 34.2% (posterior circulation aneurysms), and all-cause adverse events from 21.2% (distal ACA aneurysms) to 31.3% (posterior circulation aneurysms). Dissecting and fusiform aneurysms showed notably high rates of poor neurological outcomes (22.0%–33.3%), new deficits (25.4%–26.7%), and adverse events (26.7%–37.0%). Complexity factors significantly influenced outcomes, with prior treatment (22.9%, 19.7%, and 30.1%), calcification (16.3%, 18.1%, and 30.5%), complex angioanatomy (13.1%, 15.9%, and 26.9%), and thrombosis (19.6%, 23.9%, and 39.6%) notably increasing the risks for poor neurological outcomes, deficits, and adverse events, respectively. CONCLUSIONS This large international cohort provides contemporary benchmarks for microsurgical treatment of UIAs, emphasizing variability in outcomes based on aneurysm location, morphology, and complexity. The presented granular and quotable adverse event rates support informed patient counseling and individualized risk/benefit assessments in comparable high-volume centers.